Rocatinlimab Improves Patient-Reported Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Double-Blind Placebo-Controlled Phase 2b Study

• Үндсэн зохиолчид: Melinda Gooderham (Зохиогч), Emma Guttman-Yassky (Зохиогч), Ken Igawa (Зохиогч), Kenji Kabashima (Зохиогч), Ehsanollah Esfandiari (Зохиогч), Angela J. Rylands (Зохиогч), Angela Williams (Зохиогч), Annabel Nixon (Зохиогч), Jennifer E. Dent (Зохиогч), Eric Simpson (Зохиогч)
• Формат: Ном
• Хэвлэсэн: Adis, Springer Healthcare, 2024-11-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

Abstract Introduction In adults with moderate-to-severe atopic dermatitis (AD), rocatinlimab demonstrated significant and progressive improvement in clinical measures of disease severity compared with placebo. This post hoc analysis of a phase 2b study was undertaken to understand the disease burden...